SCHEMBL22834603

SCHEMBL22834603

CC(C)(C)OC(=O)Nc1ncc(C(=O)O)cc1OC(F)F

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.36
MAPK1 P28482 2/20 0.36
CYP3A4 P08684 1/20 0.36
LPAR1 Q92633 1/20 0.36
F11 P03951 1/20 0.35
APLNR P35414 1/20 0.35
SYK P43405 2/20 0.34
P2RX3 P56373 1/20 0.33
GAA P10253 1/20 0.33
NAMPT P43490 1/20 0.33
CACNA1H O95180 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
P2RY14 Q15391 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ATR Q13535 1/20 0.32
IDH1 O75874 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4D Q08499 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15046577 0.80 CNR2 (0.39) PDE4BPDE4D
SCHEMBL22842991 0.79 KMT2A (0.38) MAPK1SYKNAMPTPDE4D
SCHEMBL29597886 0.79 KMT2A (0.38) MAPK1SYKNAMPTPDE4D
SCHEMBL14822488 0.78 ATR (0.40) MAPTMAPK1ATR
SCHEMBL14333332 0.78 PPIA (0.48) HDAC6
SCHEMBL28718726 0.76 ALKBH1 (0.35) F11SYKPDE4BPDE4D
SCHEMBL30755736 0.75 P2RX3 (0.42) MAPTAPLNRP2RX3GAANPSR1
SCHEMBL30271368 0.72 GAA (0.44) MAPTMAPK1APLNRP2RX3GAA
SCHEMBL26633347 0.72 GSK3B (0.42) MAPK1APLNRSYKP2RX3CACNA1H
SCHEMBL30168352 0.72 AAK1 (0.41) MAPTMAPK1APLNRP2RX3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114245796-B Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of diseases 比奥根MA公司 2024-07-30 CN disclosed
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. 2023-03-23 US disclosed
EP-3990454-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Biogen MA Inc. (US) 2022-05-04 EP disclosed
CN-114245796-A Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of disease 比奥根MA公司 2022-03-25 CN disclosed
WO-2020263980-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. (US) 2020-12-30 WO disclosed
WO-2020263980-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. (US) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE IRAK4, IRAK2, IRAK1 MAPT 3364/4885MAPK1 308/4885CYP3A4 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.